Vertel uw vrienden over dit artikel:
Exploring Systemic Options for Advanced Hepatocellular Carcinoma Omar Abdel-rahman
Exploring Systemic Options for Advanced Hepatocellular Carcinoma
Omar Abdel-rahman
The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m2 twice daily) (day 1?day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety.
| Media | Boeken Paperback Book (Boek met zachte kaft en gelijmde rug) |
| Vrijgegeven | 25 juli 2013 |
| ISBN13 | 9783659430138 |
| Uitgevers | LAP LAMBERT Academic Publishing |
| Pagina's | 168 |
| Afmetingen | 150 × 10 × 225 mm · 268 g |
| Taal en grammatica | Duits |
Meer door Omar Abdel-rahman
Bekijk alles van Omar Abdel-rahman
Kerstcadeautjes kunnen tot en met 31 januari worden ingewisseld